Short Interest in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Increases By 8.1%

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 9,500,000 shares, a growth of 8.1% from the December 31st total of 8,790,000 shares. Approximately 7.6% of the shares of the stock are short sold. Based on an average trading volume of 1,670,000 shares, the days-to-cover ratio is presently 5.7 days.

Wall Street Analyst Weigh In

HALO has been the topic of a number of recent research reports. JMP Securities lifted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Piper Sandler lifted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. HC Wainwright upped their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Finally, Wells Fargo & Company cut their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $60.89.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.70% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of HALO. Heck Capital Advisors LLC bought a new position in Halozyme Therapeutics during the fourth quarter valued at $29,000. GAMMA Investing LLC lifted its stake in shares of Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares during the last quarter. Toth Financial Advisory Corp bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $57,000. FSC Wealth Advisors LLC bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $65,000. Finally, Venturi Wealth Management LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $69,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $56.28 on Tuesday. The company has a market cap of $7.16 billion, a PE ratio of 18.64, a price-to-earnings-growth ratio of 0.43 and a beta of 1.25. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53. The business has a 50 day moving average price of $50.82 and a 200-day moving average price of $54.33. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.